Steve Assanti from my 600lbs life. As unhealthy as you can be yet rocks a thick NW1. Chat 5/19/2026
Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Need supplemental products in addition to oral minoxidil and oral dutasteride
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
community Do we know exactly why some people respond so great to dut/fin,min and others dont?
Genetic factors, enzyme activity, and DHT sensitivity affect individual responses to hair loss treatments like finasteride, minoxidil, and dutasteride. Starting treatments early can slow hair loss, but results vary among individuals.
community If DHT is the cause of hair loss why do so many still lose hair on dutasteride?
Hair loss can persist despite using treatments like finasteride, dutasteride, and minoxidil due to factors like genetic sensitivity, incomplete DHT blockage, and other hormonal influences. Individual responses vary, and some may require a combination of treatments to stabilize hair loss.
community Why do some people (specially those with diffuse balding) experience more regrowth just with DHT blockers?
Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.
community Having androgen receptor density and sensitivity at wrong f*ing place
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
Related Research
6 / 6 resultsresearch Medical management of male pattern hair loss
This article discusses the medical management of male pattern hair loss and reports no new clinical findings.
research ANDROGENETIC ALOPECIA: A REVIEW OF CURRENT THERAPEUTIC OPTIONS
This review outlines that minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective treatments for androgenetic alopecia, with additional therapies like platelet-rich plasma and hair transplantation enhancing results, emphasizing the need for individualized, combination approaches.
research How to treat androgenetic alopecia – the most common form of hair loss. A review
This review outlines current treatments for androgenetic alopecia, highlighting the efficacy and side effects of FDA-approved options like minoxidil and finasteride, and emphasizes the necessity of long-term use and careful patient collaboration to avoid adverse reactions.
research Androgenetic alopecia: An update
This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.
research Androgenetic Alopecia in Gender Minority Patients
This study highlights the importance of clinicians understanding the effects of gender-affirming hormones like testosterone, estrogen, and antiandrogens on hair growth, to effectively diagnose and treat androgenetic alopecia in gender minority patients.
research Molecular mechanisms of androgenetic alopecia
This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.